Context Existing therapies for major depression have a lag of onset of action of several weeks,
resulting in considerable morbidity. Exploring pharmacological strategies that have rapid …

Major depressive disorder affects around 16 per cent of the world population at some point
in their lives. Despite the availability of numerous monoaminergic-based antidepressants, …

BACKGROUND: Ketamine exerts a robust, rapid, and relatively sustained antidepressant
effect in patients with major depression. Understanding the mechanisms underlying the …

Context Existing therapies for bipolar depression have a considerable lag of onset of action.
Pharmacological strategies that produce rapid antidepressant effects—for instance, within a …

Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of
millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, …

Ketamine, a racemic mixture consisting of (S)- and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

BACKGROUND: Currently, no pharmacological treatments for bipolar depression exist that
exert rapid (within hours) antidepressant or antisuicidal effects. We previously reported that …

Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Objective: Suicidal ideation is a medical emergency, especially when severe. Little research
has been done on pharmacologic interventions that could address this problem. Ketamine, …

Objective The risk-benefit profile of antidepressant medications in bipolar disorder is
controversial. When conclusive evidence is lacking, expert consensus can guide treatment …